These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 30947876

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Hepatobiliary disease in cystic fibrosis].
    Pérez-Aguilar F, Berenguer Lapuerta J.
    Med Clin (Barc); 1998 Sep 19; 111(8):302-6. PubMed ID: 9810550
    [No Abstract] [Full Text] [Related]

  • 5. Cystic fibrosis-associated liver disease.
    Herrmann U, Dockter G, Lammert F.
    Best Pract Res Clin Gastroenterol; 2010 Oct 19; 24(5):585-92. PubMed ID: 20955961
    [Abstract] [Full Text] [Related]

  • 6. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
    Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK.
    Liver Int; 2007 Dec 19; 27(10):1402-8. PubMed ID: 18036103
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Current Treatment Options for Cystic Fibrosis-Related Liver Disease.
    Staufer K.
    Int J Mol Sci; 2020 Nov 14; 21(22):. PubMed ID: 33202578
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
    Colombo C, Crosignani A, Battezzati PM, Castellani MR, Comi S, Melzi ML, Giunta A.
    J Hepatol; 1999 Oct 14; 31(4):672-7. PubMed ID: 10551391
    [Abstract] [Full Text] [Related]

  • 12. Prevalence and characteristics of cystic fibrosis liver disease: a study highlighting the lack of histological diagnosis.
    Issa Z, Gohy S, Zech F, Baldin P, Delire B, Dahlqvist G.
    Clin Res Hepatol Gastroenterol; 2022 Nov 14; 46(9):101977. PubMed ID: 35772685
    [Abstract] [Full Text] [Related]

  • 13. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006.
    Nash KL, Allison ME, McKeon D, Lomas DJ, Haworth CS, Bilton D, Alexander GJ.
    J Cyst Fibros; 2008 May 14; 7(3):252-7. PubMed ID: 18042441
    [Abstract] [Full Text] [Related]

  • 14. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert TF, Berteloot L, Vilgrain V.
    J Hepatol; 2022 Feb 14; 76(2):420-434. PubMed ID: 34678405
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ursodeoxycholic acid for cystic fibrosis-related liver disease.
    Cheng K, Ashby D, Smyth RL.
    Cochrane Database Syst Rev; 2014 Dec 15; (12):CD000222. PubMed ID: 25501301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.